Core Viewpoint - The article provides an overview of the financing events in the primary market, highlighting the increase in both the number of financing events and the total financing amount compared to the previous week, indicating a growing interest in investment opportunities across various sectors [4][12]. Financing Overview - As of May 23, 2025, there were 130 financing events reported, an increase of 42 events from the previous week, with a total financing amount of approximately 3.828 billion RMB, up by 749 million RMB [4]. - Among these events, 19 had financing amounts of 100 million RMB or more, which is an increase of 3 events from the previous week [4]. - There were 33 public exit cases this week, remaining stable compared to last week [4]. Financing Amount Distribution - A total of 80 financing events disclosed their amounts, with the distribution as follows: - 8 events under 5 million RMB (up by 4) - 39 events between 5 million and 10 million RMB (up by 10) - 11 events between 10 million and 50 million RMB (down by 2) - 19 events between 50 million and 100 million RMB (up by 7) - 3 events between 100 million and 500 million RMB (down by 2) - No events above 500 million RMB [5]. Notable Investment Events - **Satellite Operations**: Penghu Wuyu completed nearly 100 million RMB in Series A financing, led by Wuxi Liangxi Kechuang Industry Mother Fund and Wuxi Liangxi Aerospace Investment Fund, to expand its global operations in satellite IoT [7]. - **Organoids**: Chuangxin International raised nearly 100 million RMB in Series B financing, led by Yueke Fund and Donghai Investment, to accelerate the development of organoid technology [7]. - **Resource Recovery**: Zhongwu Industry Operations secured 500 million RMB in Series A financing to enhance its procurement network and improve supply chain efficiency [8]. - **AI Chips**: Blue Core Computing raised over 100 million RMB in equity financing, with participation from multiple investment institutions, focusing on high-performance chip design [8]. Industry Distribution - The financing events spanned 14 industries, with the top five being: - Healthcare: 28 events - Electronics: 25 events - Information Technology: 19 events - Equipment Manufacturing: 14 events - Consumer Goods and Services: 14 events - These five industries accounted for 76.15% of all financing events [12]. Financing Amount by Industry - The top five industries by financing amount were: - Healthcare: 32.07 million RMB (83.76% of total) - Information Technology: Significant contributions from Whale and other major events - Consumer Goods and Services - Electronics - Equipment Manufacturing - The healthcare sector led with a high number of large financing events [14]. Regional Distribution - The top five regions for financing events were: - Jiangsu: 29 events - Guangdong: 22 events - Zhejiang: 22 events - Beijing: 16 events - Shanghai: 9 events - These regions accounted for 75.38% of all financing events [17]. - In terms of financing amount, Zhejiang led with 829.59 million RMB, influenced by significant events [17]. Financing Rounds - The most active financing rounds were Angel and Series A, totaling 74 events, with Series B ranking third at 23 events [22]. - Series A financing accounted for 37.16% of the total financing amount, followed by strategic financing at 16.09% [22]. Investment Institutions - A total of 129 investment institutions participated in financing activities, with notable activity from Beijing Guoguan and Shenzhen Capital Group [25]. Exit Situation - There were 33 public exit cases, with the healthcare sector leading in the number of exits, followed by materials and electronics [30][31].

Core Insights - Chuangxin International has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2] - The company focuses on precision medicine, new drug development, and intelligent manufacturing, aiming to overcome key industry bottlenecks and promote the intelligent, standardized, and industrialized development of the organoid industry [2][3] - The FDA's new regulation set to be released in April 2025 will phase out animal testing models, recommending human cell models, including organoids, marking a shift towards more realistic human models in life sciences research [2] Company Overview - Chuangxin International Biotech (Guangzhou) Co., Ltd. was established in March 2018 and has built a comprehensive ecosystem covering the entire lifecycle of organoid technology [2] - The company is positioned as a global leader in organoid technology, redefining core pathways in life sciences research through technological innovation and ecosystem reconstruction [3] - The CEO, Dr. Huang Min, stated that the company will leverage this financing round to enhance its technology platform, data intelligence, and industrial applications, aiming to create a product matrix in key areas such as organoid intelligent devices and data systems [3]

Core Insights - Chuangxin International Biotechnology (Guangzhou) Co., Ltd. has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2][3] - Organoids, derived from stem cells and cultivated in 3D, closely mimic the genetic characteristics and structure of the source tissue, making them crucial tools in precision medicine and innovative drug development [2] - The global life sciences research paradigm is shifting from animal models to human cell models, with the FDA planning to phase out animal testing by April 2025, recommending the use of organoids [2] Company Overview - Chuangxin International is a full-chain innovative enterprise in the organoid field, focusing on precision medicine, new drug development, and intelligent manufacturing [2] - The company has established a comprehensive ecosystem covering the entire lifecycle of organoids, aiming to drive the industry towards intelligence, standardization, and industrialization [2] Investment Perspective - Yueke Fund recognizes Chuangxin International's leading organoid technology and its significant application value in precision medicine and new drug development, aligning with its investment philosophy [3] - The investment from Tohoku East, which focuses on early to mid-stage tech enterprises, is seen as a strategic move to enhance the development of the biomedical industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area [3] Future Plans - Chuangxin International plans to leverage this financing round to build a technology ecosystem covering the entire lifecycle of organoids, focusing on core technology research and product innovation [3] - The company aims to create a product matrix in key areas such as organoid intelligent devices, chips, and data intelligence systems, striving to become a global leader in the organoid industry [3]